HighGravityDataEdwards Lifesciences — Jul 23, 2026 release
Fiscal 2026 second-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0001099800-26-000038
Showing in the filing
Gross profit margin
“at the lower end of its full-year 78% to 79%”
Period
FY2026
Measure
GAAP-tied
Source
Prose
All guidance in this release · 16
Total company sales growth (constant currency) for FY2026
“10% to 11%”
TAVR sales growth (constant currency) for FY2026
“8% to 9%”
TMTT product group sales for FY2026
“$760 to $780 million”
Adjusted EPS for FY2026
“$2.95 to $3.05”
Adjusted EPS growth at midpoint for FY2026
“17% at midpoint”
Total company sales growth target, longer term for the long term
“approximately 10% total company sales growth, on average”
Gross profit margin for FY2026
“at the lower end of its full-year 78% to 79%”
Gross profit margin for FY2026
“lower end of its full-year 78% to 79% gross margin guidance”
R&D expense as a percentage of sales for FY2026
“approximately 17%”
Operating profit margin for FY2026
“high end of the company’s original 28% to 29% guidance range”
Constant currency operating margin expansion for FY2026
“approximately 150 basis points”
Effective tax rate, excluding special items for FY2026
“at the high end of its previous range of 16% to 19%”
Total company sales for FY2026
“$6.6 billion to $6.9 billion”
TAVR sales for FY2026
“$4.75 billion to $5.0 billion”
Total sales for Q3 FY2026
“between $1.63 and $1.71 billion”
Adjusted EPS for Q3 FY2026
“$0.71 to $0.77”
Exhibit 99.1 · the passage around this item
… earlier in the release
Additional Financial Results For the quarter, gross profit margin was 77.5%, or 77.6% adjusted, consistent with the same period last year and driven by foreign exchange headwinds offset by lower manufacturing expenses. The company now expects gross profit margin to be at the lower end of its full-year 78% to 79% gross margin guidance, driven by the impacts of foreign exchange through its hedging program. Selling, general and administrative expenses in the second quarter were $561 million, or 32.2% of sales, compared to 32.8% of sales in the prior year. This was in line with the company’s expectations and reflects continued investment in resources to support patient care as well as a higher translation of the company’s OUS expense base from the weakening dollar. Research and Development (R&D) expenses 3 in the second quarter were $279 million, or 16.0% of sales, compared to 18.0% in the prior year. This decrease in R&D as a percentage of sales and increase in total expense reflects Edwards’ growing revenue and strategic prioritization of investments in its expanding structural heart portfolio. The company continues to expect R&D expense as a percentage of sales to be approximately 17% in 2026. Operating profit margin in the second quarter was 29.5%, or 30.0% adjusted. Adjusted EPS was $0.78 and benefited from better-than-expected topline performance and planned phasing of strategic investments in R&D and SG&A throughout the year. In 2026, Edwards continues to expect full-year operating pro
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.